Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
80 hedge funds and large institutions have $240M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2017 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 30 increasing their positions, 5 reducing their positions, and 2 closing their positions.
1,200% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 2
500% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 5
87% more capital invested
Capital invested by funds: $129M → $240M (+$112M)
40% more funds holding
Funds holding: 57 → 80 (+23)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $376K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13.2M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$11.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.77M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$7.52M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$1.11M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$734K |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$254K |
| 4 |
JP Morgan Chase
New York
|
-$119K |
| 5 |
CC
Capital Counsel
New York
|
-$113K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Canada Life
Winnipeg,
Manitoba, Canada
| $28K | – | – | – |
|
77
BNP Paribas Financial Markets
Paris,
France
| $26.5K | -$2.17K | -72 | -8% |
|
|
AIP
78
Ameritas Investment Partners
Lincoln,
Nebraska
| $22K | – | – | – |
|
79
Simplex Trading
Chicago,
Illinois
| $3K | +$3.01K | +100 | New |
|
|
MAM
80
Meeder Asset Management
Dublin,
Ohio
| $2K | +$1.59K | +53 | New |
|
|
81
Renaissance Technologies
New York
| – | -$1.11M | -35,200 | Closed |
|
|
82
Russell Investments Group
London,
United Kingdom
| – | -$254K | -8,012 | Closed |
|
RETA Hedge Fund Activity: Q3 2017 in Review
80 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q3 2017, worth a combined $240M — up 87% from $129M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new RETA positions and 2 closed out — a net gain of 24 holders — while 30 added to existing stakes and 5 trimmed.
The largest buyer was BlackRock, adding an estimated $13.2M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $1.11M sold.
- 80 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q3 2017, up from 57 in Q2 2017.
- Funds reported $240M of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q3 2017, up 87% quarter-over-quarter.
- 26 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q3 2017 and 2 closed out, a net change of +24 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q3 2017 was BlackRock, an estimated $13.2M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q3 2017 was Renaissance Technologies, an estimated $1.11M sold.
Based on aggregated 13F filings for Q3 2017.